Everforth Inc quarterly report, Q1 FY2013

Business context and reporting period

The filing is an unaudited Form 10-Q for the three months ended March 31, 2013. Although the request metadata names Everforth Inc, the filing identifies the registrant as On Assignment, Inc. and its subsidiaries, a staffing provider serving technology, healthcare and life sciences markets. Results include five reportable segments: Apex, Oxford, Life Sciences, Physician and Healthcare.

Key financial results

MetricQ1 2013Q1 2012
Revenue$389.2 million$156.8 million
Gross profit / margin$113.3 million / 29.1%$52.7 million / 33.6%
Operating income / margin$23.7 million / 6.1%$9.4 million / 5.9%
Income from continuing operations$10.6 million$5.0 million
Net income$24.6 million$5.4 million
Net cash from operating activities$3.6 million$7.0 million
  • Net income included a $14.4 million after-tax gain on the sale of the Nurse Travel division; continuing-operations income is a better measure of ongoing earnings.
  • Q1 2013 diluted EPS was $0.46, including $0.26 from discontinued operations; diluted EPS from continuing operations was $0.20.
  • Cash and cash equivalents were $11.8 million at March 31, 2013, including $7.7 million held abroad that the company said it did not intend to repatriate. Working capital was $166.5 million.
  • Total debt was $383.6 million, down from $426.6 million at December 31, 2012, following $43.0 million of principal payments. The weighted average borrowing rate was 4.6%; $72.0 million was available under the credit facility.
  • The company reported a 2.49-to-1.00 leverage ratio and compliance with debt covenants. A hypothetical 1 percentage-point rate change was estimated to alter annual interest expense by about $3.6 million after hedges.

Material changes versus the prior period

  • Revenue rose 148.3%, primarily because of the May 2012 acquisition of Apex, which contributed $212.7 million, or 54.7% of Q1 2013 revenue. Management reported 12.6% year-over-year growth across the other business segments; the total increase should not be interpreted as organic growth.
  • Consolidated gross margin fell 450 basis points, mainly reflecting Apex’s lower-margin business mix. SG&A increased to $84.2 million, including $38.3 million from Apex; as a share of revenue, SG&A declined to 21.6% from 27.3%.
  • Interest expense rose to $5.3 million from $0.7 million, primarily because of debt incurred to finance the Apex acquisition. Amortization increased to $5.4 million from $0.6 million, largely due to acquired intangible assets.
  • Oxford revenue grew 21.0%; Physician grew 9.2%; Healthcare grew 14.9%; and Life Sciences declined 2.1%. Physician and Life Sciences gross margins contracted, while Healthcare gross profit increased.
  • On February 12, 2013, the company sold Nurse Travel for $31.0 million cash. The division was presented as discontinued operations; it had a Q1 operating loss after tax of $0.4 million, versus $0.3 million of income in Q1 2012.
  • Despite higher net income, operating cash flow declined to $3.6 million, primarily due to changes in operating assets and liabilities, including a $26.1 million accounts-receivable outflow.

Outlook, risks and unusual items

  • Management expected to replace the existing credit facility with a new $500 million facility by mid-May 2013, stating it would provide greater flexibility at a lower effective borrowing rate. The filing does not provide final terms or confirmation of completion.
  • Management estimated 2013 capital expenditures of approximately $16 million and said working capital, credit availability and expected operating cash flows should fund requirements for the next 12 months.
  • Potential acquisition earn-out payments were approximately $8.9 million through 2013. The company also reported $10.5 million of workers’ compensation and medical malpractice reserves and $3.0 million of related letters of credit.
  • Management cited economic uncertainty, demand for staffing, attracting and retaining staffing consultants and qualified professionals, competition, growth management and information-systems performance as risks. Staffing demand is typically lower in the first and fourth quarters; first-quarter payroll-tax resets also tend to increase costs.
  • The company said pending ordinary-course legal matters were not expected to have a material effect. It reported effective disclosure controls and no material change in internal control over financial reporting during the quarter.

Important facts for investors to verify

  • Confirm the issuer identity: the supplied metadata says Everforth Inc, while this filing is for On Assignment, Inc.
  • Assess the sustainability of revenue and earnings growth apart from the Apex acquisition and the Nurse Travel sale gain.
  • Review cash conversion, receivables growth and working-capital needs alongside reported earnings.
  • Verify completion and final terms of the proposed $500 million credit facility, debt amortization requirements and covenant headroom.
  • Monitor gross-margin trends, segment performance, earn-out estimates and the effect of interest rates on debt costs.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.